Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Puma Biotechnology (PBYI) Accounts Payables (2017 - 2025)

Puma Biotechnology (PBYI) has disclosed Accounts Payables for 9 consecutive years, with $5.1 million as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Accounts Payables fell 8.22% year-over-year to $5.1 million, compared with a TTM value of $5.1 million through Dec 2025, down 8.22%, and an annual FY2025 reading of $5.1 million, down 8.22% over the prior year.
  • Accounts Payables was $5.1 million for Q4 2025 at Puma Biotechnology, down from $6.4 million in the prior quarter.
  • Across five years, Accounts Payables topped out at $20.0 million in Q3 2021 and bottomed at $5.1 million in Q4 2025.
  • Average Accounts Payables over 5 years is $8.9 million, with a median of $7.7 million recorded in 2023.
  • The sharpest move saw Accounts Payables crashed 66.09% in 2023, then surged 73.19% in 2024.
  • Year by year, Accounts Payables stood at $11.2 million in 2021, then tumbled by 42.37% to $6.4 million in 2022, then grew by 6.97% to $6.9 million in 2023, then decreased by 20.03% to $5.5 million in 2024, then decreased by 8.22% to $5.1 million in 2025.
  • Business Quant data shows Accounts Payables for PBYI at $5.1 million in Q4 2025, $6.4 million in Q3 2025, and $5.4 million in Q2 2025.